Home » Clinical Trials » Spinal muscular atrophy » NCT06288230
NCT06288230

Study of AAV-hSMN1 (Vesemnogene Lantuparvovec) Gene Therapy in Subjects With Progressive Spinal Muscular Atrophy

Study Summary

This is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.

Interested in this trial?

Submit an Inquiry

Interventions

vesemnogene lantuparvovecBIOLOGICAL
Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.

Study Locations

FacilityCityStateCountry
Kunming Hope of Health HospitalKunmingYunnanChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026